Geron (NASDAQ:GERN – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.

Geron stock opened at $1.64 on Wednesday. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -5.13 and ...

John Scarlett; Chairman of the Board, President, Chief Executive Officer; Geron Corp Jim Ziegler; Executive Vice President, Chief Commercial Officer; Geron Corp Joseph Eid; Executive Vice ...

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call that sales of its lead drug Rytelo appear to be slowing. For Q4 ...

FOSTER CITY, Calif., March 11, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer ...

Geron stock is seeing a dramatic pullback following the company's fourth-quarter report. Geron's earnings in Q4 fell short of Wall Street's expectations, and management had worrying guidance for ...

Geron (GERN) Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the treatment of adult patients with transfusion-dependent ...

Geron (GERN) Corporation announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Rytelo's market share in second-line LR-MDS is ...

FOSTER CITY, Calif. - Geron Corporation (NASDAQ:GERN), a $1.03 billion market cap biopharmaceutical company specializing in blood cancer treatments, announced today the departure of Dr. John "Chip" A.

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.